The top ETF stories so far this second quarter linger around upbeat U.S. economic data points and the U.S.-China trade talks.
The top ETF stories so far this second quarter linger around upbeat U.S. economic data points and the U.S.-China trade talks.
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank #1 or 2 which are expected to outperform in the quarter ahead.
We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank #1 or 2 which are expected to outperform in the quarter ahead.
These ETFs are in the green this year and are up for more gains.
These ETFs are in the green this year and are up for more gains.
Inside the top ETF events of the month of February.
Inside the top ETF events of the month of February.
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
